Xie Xiaohong, Bao Shangyi, Zhao Hong, Li Liuying, Fu Xiaojun
Respiratory Department, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Hematology Department, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Cancer Invest. 2023 Feb 2:1-13. doi: 10.1080/07357907.2023.2174261.
To fully investigate the efficacy and safety of bevacizumab for glioblastoma.
Databases were searched for phase II/III randomized controlled trials treated with bevacizumab.
Bevacizumab significantly improved the PFS in glioblastoma patients, but did not prolong OS. PFS was significantly prolonged in both first-line and second-line treatment. Bevacizumab plus temozolomide was correlated with improved PFS for patients with different MGMT methylation status. Bevacizumab could increase the risk of hypertension, proteinuria, thromboembolic, and infection. Hypertension should be well concerned.
Bevacizumab-containing regimen can significantly improve PFS, but did not prolong OS.
全面研究贝伐单抗治疗胶质母细胞瘤的疗效和安全性。
检索数据库中使用贝伐单抗治疗的II/III期随机对照试验。
贝伐单抗显著改善了胶质母细胞瘤患者的无进展生存期（PFS），但未延长总生存期（OS）。一线和二线治疗中PFS均显著延长。贝伐单抗联合替莫唑胺对不同O-甲基鸟嘌呤-DNA甲基转移酶（MGMT）甲基化状态的患者，其PFS改善相关。贝伐单抗可增加高血压、蛋白尿、血栓栓塞和感染的风险。高血压应予以密切关注。
含贝伐单抗方案可显著改善PFS，但未延长OS。
